MDL | - |
---|---|
Molecular Weight | 304.34 |
Molecular Formula | C15H20N4O3 |
SMILES | [O-][N+](C1=CC(C(C(C)C2)=NNC2=O)=CC=C1N(CC)CC)=O |
DNMDP, a phosphodiesterase 3A (PDE3A) inhibitor, is a potent and selective cancer cell cytotoxic agent. DNMDP binding to PDE3A promotes an interaction between PDE3A and Schlafen 12 (SLFN12). DNMDP shows clear cell-selective cytotoxicity [1] .
DNMDP (0-1000 μM; 48 hours) shows clear cell-selective cytotoxicity
[1]
.
HeLa cells undergo apoptosis upon DNMDP treatment, indicates by caspase activity detected by a caspase-sensitive luciferase assay and by poly ADP ribose polymerase (PARP) cleavage. At a concentration of 100 nM, DNMDP specifically inhibits both PDE3A and PDE3B, weakly inhibits PDE10, and had little or no detectable effect on other phosphodiesterases
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
Cell Line: | NCI-H1563, NCI-H2122, HeLa, A549, MCF7, and PC3 cells |
Concentration: | 0-1000 μM |
Incubation Time: | 48 hours |
Result: | Showed an EC 50 between 10 and 100 nM for two additional lung adenocarcinoma cell lines, NCI-H1563 and NCI-H2122, and for HeLa cervical carcinoma cells, but an EC 50 greater than 1 µM for A549, MCF7, and PC3 cells. |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 50 mg/mL ( 164.29 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.2858 mL | 16.4290 mL | 32.8580 mL |
5 mM | 0.6572 mL | 3.2858 mL | 6.5716 mL |
10 mM | 0.3286 mL | 1.6429 mL | 3.2858 mL |
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (8.21 mM); Clear solution